<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                            NIH Public Access <br />                             Author Manuscript <br />                             J Biol Chem. Author manuscript; available PMC 2013 October 07. <br />                            Published final edited form  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             J Biol Chem. 1999 December 31; 274(53): 37781&#226;&#8364;&#8220;37786. <br />  <br />  <br />  <br />                            Essential Protein-Protein Interactions Plasmodium <br />                            falciparum Thymidylate Synthase Dihydrofolate Reductase <br />                            Domains* <br />                            Shamira Shallom, Kai Zhang, Lei Jiang, Pradipsinh K. Rathod&#226;&#8364;&#161; <br />                            Department Biology, Catholic University America, Washington, D. C. 20064 <br />  <br />                            Abstract <br />                                 Plasmodium falciparum, dihydrofolate reductase thymidylate synthase activities                                 conferred single 70-kDa bifunctional polypeptide (DHFR-TS, dihydrofolate reductase- <br />                                 thymidylate synthase) assembles functional 140-kDa homodimer. mammals,                                 enzymes smaller distinct molecules encoded different genes. 27-kDa amino domain <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                 malarial DHFR-TS sufficient provide DHFR activity, structural requirements                                 TS function established. 3&#226;&#8364;&#178;-end DHFR-TS high homology                                 TS sequences species, expression protein fragment failed yield active TS <br />                                 enzyme, failed complement TS&#226;&#710;&#8217; Escherichia coli. Unexpectedly, partial 5&#226;&#8364;&#178;-deletion <br />                                 length DHFR-TS gene abolished TS function 3&#226;&#8364;&#178;-end.  hypothesized                                 amino end bifunctional parasite protein plays important role TS function.                                 27-kDa amino domain (DHFR) provided trans, previously inactive 40-kDa carboxyl- <br />                                 domain malarial DHFR-TS regained TS function. Physical characterization &#226;&#8364;&#339;split <br />                                 enzymes&#226;&#8364;? revealed 27- 40-kDa fragments DHFR-TS reassembled                                 140-kDa hybrid complex.  malarial DHFR-TS, physical interactions                                 DHFR domain TS domain, interactions necessary obtain catalytically <br />                                 active TS. Interference essential protein-protein interactions lead new selective <br />                                 strategies treat malaria resistant traditional DHFR-TS inhibitors. <br />  <br />                                              Malaria, caused protozoan parasite Plasmodium falciparum, affects 300 million <br />                                              individuals causes 2 million death year (1). Traditional antimalarial agents <br />                                              chloroquine ineffective regions world drug resistance (2, <br />                                              3). addition, mounting evidence highly drug-resistant parasite clones acquire <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              resistance new antimalarial agents enhanced rate (4, 5). Identification host- <br />                                              parasite biochemical differences lead selective chemotherapy important <br />                                               <br />  <br />                                              malaria cell types, chemotherapy targeted dihydrofolate <br />                                              reductase (DHFR)1 thymidylate synthase (TS) proven highly effective (6, 7). <br />                                              partial inhibition DHFR TS lead DNA strand fragmentation cell death <br />                                              (8 &#226;&#8364;&#8220;10). malaria pharmacology, enzymes particular  <br />  <br />                             work supported United States Public Health Service Grants AI26912 AI40956 National Institutes                            Health. <br />                            &#194;&#169; 1999 American Society Biochemistry Molecular Biology,  <br />                            correspondence addressed: Dept. Biology, Catholic University America, 620 Michigan Ave., N.E., <br />                            Washington D. C. 20064. Tel.: 202-319-5278; Fax: 202-319-5721; rathod@cua.edu. <br />                            &#226;&#8364;&#161;Recipient Burroughs Wellcome Fund New Initiatives Malaria Research award. <br />                            1The abbreviations used  DHFR, dihydrofolate reductase; TS, thymidylate synthase. <br />                             Shallom et al.                                                                                            Page 2 <br />  <br />  <br />                                             traditional drugs pyrimethamine cycloguanil known inhibit parasite <br />                                             DHFR-TS (11&#226;&#8364;&#8220;13). recent years,  effectiveness inhibitors                                             compromised malarial parasite strains expressing mutant forms DHFR-TS (14 &#226;&#8364;&#8220;16). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             obvious way continue selective killing malarial parasites identify new folate <br />                                             analogs directed DHFR- TS-active sites effective drug-resistant <br />                                             parasites (17&#226;&#8364;&#8220;20). <br />  <br />                                             active site-directed strategies, non-traditional opportunities inhibit <br />                                             malarial DHFR-TS selectivity. protozoan parasites, including Plasmodia,                                             single bifunctional protein codes DHFR TS activity (21&#226;&#8364;&#8220;24). sharp <br />                                             contrast, mammalian cells  bacteriophage, bacteria, yeast) separate <br />                                             genes code small monofunctional DHFR TS proteins (25, 26). difference                                             organization established drug targets represents dramatic difference host- <br />                                             parasite biochemistry.  clear bifunctional status DHFR-TS <br />                                             play role selective chemotherapy.  indications active sites                                             DHFR TS bifunctional proteins operate independently  Inhibition <br />                                             DHFR methotrexate does influence TS activity, inhibition TS function <br />                                             5-fluoro-2&#226;&#8364;&#178;-deoxyuridylate does effect DHFR activity (27). structure                                             Leishmania DHFR-TS suggests active sites DHFR-TS 40 &#195;&#8230; apart (28). <br />                                             Designing &#226;&#8364;&#339;double-barrel,&#226;&#8364;? parasite-specific bifunctional DHFR-TS inhibitor                                             practical goal present. Second, kinetic measurements suggest Leishmania NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Toxoplasma TS channel 8 10 dihydrofolate (DHF) molecules directly <br />                                             TS site DHFR site (27, 29, 30).  Leishmania DHFR-TS structure <br />                                             indicates direct channeling attributed electropotential gradient                                             bifunctional protein leads TS folate-binding site DHFR folate-binding <br />                                             site (28, 29).  highly unlikely blocking channeling lead                                             selective antimalarial chemotherapy malarial DHFR-TS active sites                                             trouble delivering accepting substrates bulk solvent vitro (31, 32) vivo <br />                                             (33). <br />  <br />                                             study, demonstrate species-specific interactions malarial DHFR <br />                                             domain TS domain essential functioning enzymes. Inhibition                                             protein-protein interactions offer powerful new strategy selective chemotherapy <br />                                             malaria possibly protozoan parasites. <br />  <br />                               EXPERIMENTAL PROCEDURES <br />                               Materials <br />                                             Trimethoprim, ampicillin, tetracycline, leucine, proline, <span id='am-8' about='obo:IMR_0200384' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-9' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:id" content="IMR:0200384" datatype="xsd:string"></span><span id='am-11' property="rdfs:label" content="Thymidine" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasDbXref" content="KEGG:C00214" datatype="xsd:string"></span>thymidine</span>, 2&#226;&#8364;&#178;-deoxyuridylate, 5- <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             fluoro-2&#226;&#8364;&#178;-deoxyuridylate, dihydrofolate, methotrexate-agarose Sigma. <br />                                             Oligonucleotides synthesized Operon (Alameda, CA). Escherichia coli strains <br />                                             BL21, BL21(DE3), DE3 lysogenization kit Novagen (Madison, WI). E. <br />                                             coli strain Rue10 (thyA&#226;&#710;&#8217;) Chen-Chen Kan (Agouron Pharmaceuticals). <br />  <br />                               Plasmids <br />                                             Plasmid pKK233.2 P. falciparum DHFR-TS coding sequence clone K1                                             obtained John Hyde (University Manchester) maintained described <br />                                             previously (34). Plasmids pET23d(+) Novagen (Madison, WI). plasmid <br />                                             cut NcoI HindIII modified express different domains P. falciparum <br />                                             DHFR-TS (Fig. 1). pET-DHFR designed express amino acids 1&#226;&#8364;&#8220;230 P. <br />                                             falciparum DHFR-TS coding region (32, 34); pET-TS31 expressed amino acids 325&#226;&#8364;&#8220; 607                                             P. falciparum DHFR-TS coding region; pET-TS40 coded amino acids 249 &#226;&#8364;&#8220; 607 <br />  <br />  <br />                                                 J Biol Chem. Author manuscript; available PMC 2013 October 07. <br />                             Shallom et al.                                                                                           Page 3 <br />  <br />  <br />                                             P. falciparum DHFR-TS coding region, pET-DHFR-TS contained length <br />                                             coding region (Fig. 1). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Antibody P. falciparum DHFR Domain <br />                                             antigen, malarial DHFR domain, expressed purified methotrexate-affinity <br />                                             column described previously (32). Rabbit polyclonal antibodies pure protein                                             raised Josman Laboratories (Napa, CA). P. falciparum DHFR-specific antibody                                             purified affinity chromatography using P. falciparum DHFR domain attached                                             Aminolink Plus Pierce. <br />  <br />                               Genetic Complementation Assay TS Function <br />                                             thymidylate synthase-deficient E. coli strain Rue10 lysogenized &#206;&#187;DE3                                             provide T7 RNA polymerase function host (36). host cells maintained                                             LB medium presence leucine (40 &#206;&#188;g/ml), proline (200 &#206;&#188;g/ml), thymidine (100 <br />                                             &#206;&#188;g/ml). testing TS function pET plasmids bearing malarial DHFR-TS gene,                                             portions gene, 50 ng plasmid electroporated 4 &#195;&#8212; 107 <br />                                             electrocompetent Rue10(DE3) cells. cells spread sets ampicillin agar <br />                                             plates, thymidine lacking thymidine. <br />  <br />                               Genetic Complementation Assay Malarial DHFR Function <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Appropriate pET plasmids electroporated BL21(DE3) cells  cells <br />                                             spread sets ampicillin agar plates, trimethoprim (50 &#206;&#188;g/ml)                                              Bacterial DHFR sensitive trimethoprim malarial DHFR (34). <br />  <br />                               Exonuclease Treatment DNA Fragment Coding Malarial DHFR-TS <br />                                             5&#226;&#8364;&#178;-deletion experiment involved following steps prior testing TS <br />                                             function:   generation DNA strand malarial DHFR-TS sequence                                             susceptible exonuclease 5&#226;&#8364;&#178;-end 3&#226;&#8364;&#178;-end; (ii) digestion long <br />                                             fragment exonuclease varying amounts time generate series short DNA <br />                                             fragments varying length; (iii) preparation recipient vector AUG start codon; <br />                                             (iv) ligation short partially digested fragments recipient vector. <br />  <br />                                             Initially, 12 &#206;&#188;g pET23d(+) plasmid length malarial DHFR-TS insert                                             digested 24 units PvuII 24 units PstI total volume 40 &#206;&#188;l 6 h.                                             purified 3900-base pair fragment containing DHFR-TS sequence susceptible                                             exonuclease III PvuII end PstI end. initiate digestion 5&#226;&#8364;&#178;-end, 6 <br />                                             &#206;&#188;g DNA placed 60 &#206;&#188;l ExoIII buffer (Erase-abase kit, Promega, Madison, WI). <br />                                             2.5-&#206;&#188;l aliquot removed time 0. Digestion started 400 units exonuclease <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             III delivered 2.3-&#206;&#188;l volume. conditions, digestion occurred rate 80 &#226;&#8364;&#8220;90 <br />                                             base pairs min 22&#226;&#8364;&#8220;25 &#194;&#176;C. Aliquotes 2.5 &#206;&#188;l removed 2.5 min 60 min. <br />                                             treated S1 nuclease blunt-ended Klenow described (Erase  <br />                                             base kit, Promega, Madison, WI). cohesive end 3&#226;&#8364;&#178;-end DHFR-TS coding <br />                                             region generated treating 2.5-min samples HindIII. <br />  <br />                                             recipient plasmid expressing exonuclease-treated DNA generated                                             cutting 5 &#206;&#188;g pET23d(+) 6 units NcoI. NcoI-digested plasmid blunt-ended <br />                                             Klenow (10 units, room temperature, 14 min) digested HindIII (24 units, <br />                                             37 &#194;&#176;C, 4 h) generate cohesive site end vector. Approximately 760 ng <br />                                             exonuclease-digested DNA (5 &#206;&#188;l) ligated 312 ng recipient vector. ligation <br />                                             products 2.5-min time point transformed electrocompetent <br />                                             Rue10(DE3) cells plated thymidine measure TS function, ligated DNA <br />  <br />  <br />                                                 J Biol Chem. Author manuscript; available PMC 2013 October 07. <br />                             Shallom et al.                                                                                          Page 4 <br />  <br />  <br />                                             transformed electrocompetent BL21(DE3) cells plated trimethoprim plates <br />                                             measure DHFR function  . <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               transformation E. coli Rue10(DE3) Plasmids Coding DHFR Fragment <br />                               TS Fragment <br />                                             step, pET-DHFR transformed Rue10(DE3) selected ampicillin <br />                                             resistance. Rue10(DE3)pET-DHFR electrocompetent, transformed                                             pET-TS40, selected growth medium lacking thymidine. Subsequently,                                             double transformants obtained transforming cells pET- <br />                                             TS40 (selection ampicillin plates) transforming pET-DHFR <br />                                             (selection medium thymidine). <br />  <br />                               Physical Characterization P. falciparum TS40 + DHFR Split Protein <br />                                             E. coli Rue10(DE3), transformed pET-DHFR pET-TS40, freshly grown                                             absorbance 1.0 600 nm. cells collected centrifugation resuspended <br />                                             50 mM Tris-HCl, pH 8, 2 mM EDTA, 0.1% Triton X-100, 0.1 mg/ml lysozyme (final <br />                                             lysis volume 1/10 original culture volume). cells incubated 30 &#194;&#176;C                                             15 min, sonicated, stored 1-ml aliquots &#226;&#710;&#8217;20 &#194;&#176;C. <br />  <br />                                             estimate native size DHFR TS activities gel filtration chromatography, <br />                                             200 &#206;&#188;l cell lysate applied 1 &#195;&#8212; 50 cm Superdex 200 column <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             (Amersham Pharmacia Biotech). buffer gel filtration 50 mM Tris-HCl, pH 8, 2 <br />                                             mM EDTA, 10% glycerol, 0.1 M NaCl, 2 mM dithiothreitol. flow rate 0.25 ml/min, <br />                                             0.5-ml fractions collected. <br />  <br />                                             split protein purified homogeneity using methotrexate affinity chromatography. <br />                                             total 10 ml cell lysate double-transformed E. coli Rue10(DE3) applied <br />                                             2-ml methotrexate-agarose column pre-equilibrated 50 mM Tris-HCl, pH 8, 2 mM <br />                                             EDTA, 10% glycerol, 0.5 M NaCl, 2 mM dithiothreitol. column washed                                             20 ml equilibration buffer active fractions eluted buffer <br />                                             plus 4 mM dihydrofolate. ml fractions collected. <br />  <br />                               Assay TS Activity Malarial DHFR Protein <br />                                             chromatography step, malarial TS activity monitored assaying 10 &#206;&#188;l                                             fraction using 5-[3H]-2&#226;&#8364;&#178;deoxyuridylate tritium release assay (34). Malarial DHFR <br />                                             activity monitored Western blotting fraction. 10-&#206;&#188;l sample tube <br />                                             applied 10% SDS-polyacrylamide gel electrophoresis                                              separation, protein transferred polyvinylidene difluoride membrane. Malarial <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             DHFR detected using affinity purified polyclonal antibodies malarial DHFR domain <br />                                              , goat anti-rabbit secondary antibodies, Western-Star chemiluminescent <br />                                             detection (Tropix, , Bedford, MA). assay easily detected 1 ng malarial <br />                                             DHFR. <br />  <br />                               RESULTS DISCUSSION <br />                               Carboxyl End Malarial DHFR-TS Insufficient TS Function <br />                                             amino-terminal DHFR domain malarial DHFR-TS expressed functional <br />                                             form (32, 34, 37, 38), attempts express carboxyl end TS domain                                             catalytically active form unsuccessful. genetic used assay TS <br />                                             function malarial DHFR-TS gene. E. coli cells lacking TS function (strain Rue10) <br />                                             normally proliferate presence thymidine absence thymidine (39). <br />                                             Lysates prepared Rue10 cells DHFR enzyme activity TS activity (data  <br />  <br />                                                 J Biol Chem. Author manuscript; available PMC 2013 October 07. <br />                             Shallom et al.                                                                                            Page 5 <br />  <br />  <br />                                             shown). Rue10 cells transformed expression plasmid coding  <br />                                             length malarial DHFR-TS gene (Fig. 1A), E. coli Rue10 proliferate absence                                             thymidine (Fig. 1B). Transformation plasmids coding minimal 30-kDa &#226;&#8364;&#339;TS <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             domain&#226;&#8364;? (Fig. 1A) 40-kDa protein coding joining region                                             TS domain (Fig. 1A) failed rescue Rue10 thymidine dependence (Fig. 1B).                                             experiments suggested carboxyl end TS domain, defined sequence homology                                             monofunctional TS proteins, sufficient express functional TS protein. <br />  <br />                               Partial 5&#226;&#8364;&#178;-Deletion Malarial DHFR-TS Abolishes TS Function <br />                                             order define minimum 5&#226;&#8364;&#178;-end functional TS domain, length malarial <br />                                             DHFR-TS gene subjected unidirectional exonuclease III treatment varying <br />                                             durations (Fig. 2A). resulting fragments blunt-ended cloned recipient <br />                                             expression vector equipped blunt-ended AUG start codon. ligation mixes <br />                                             time point transformed E. coli Rue10(DE3) scored TS function <br />                                             (colonies growing thymidine) malarial DHFR function (colonies growing                                             presence trimethoprim). results showed following:   DHFR TS function <br />                                             lost simultaneously (Fig. 2B); (ii) colony survived plates                                             thymidine, replica plated, malarial DHFR function TS function (data                                             shown); (iii) DNA sequencing inserts TS+ E. coli showed intact <br />                                             malarial DHFR-TS gene (data shown). Control experiments confirmed repeated <br />                                             recovery just length DHFR-TS inability digest gene high <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             processivity exonuclease. early 5&#226;&#8364;&#178;-digestion experiment, degradation <br />                                             malarial DHFR-TS gene visualized directly agarose gel (data shown). <br />                                             Intermediate sized fragments appropriate length observed DHFR-TS                                             treated exonuclease 5&#226;&#8364;&#8220;20 min  schematic Fig. 2A). Additionally, selection <br />                                             transformants presence thymidine allowed recovery inserts incomplete <br />                                             DHFR-TS fragments (data shown). experiments consistent                                             hypothesis &#226;&#8364;&#339;carboxyl end TS domain&#226;&#8364;? malarial parasites adequate                                             obtain functional TS enzyme. Furthermore, exonuclease experiment suggested                                             amino end malarial DHFR-TS necessary TS function. <br />  <br />                               DHFR Domain Activate TS Domain Trans <br />                                             test directly contributions malarial DHFR domain TS function, E. coli <br />                                             Rue10 transformed 40-kDa carboxyl TS domain supplemented 27- <br />                                             kDa DHFR domain trans selected medium lacking thymidine. results showed <br />                                             simultaneous transformation ThyA&#226;&#710;&#8217; E. coli expression vector coding <br />                                             40-kDa TS domain expression vector coding amino end DHFR fully <br />                                             rescued TS defect (Fig. 3). plasmids introduced order (data <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             shown). Polymerase chain reaction analysis demonstrated TS function truly <br />                                             restored genes acting trans. distinct plasmids rescued E. coli, <br />                                             evidence new bifunctional gene created recombination <br />                                             plasmids (data shown). Direct biochemical TS assay cell lysates showed <br />                                              expected, double transformed E. coli proliferated thymidine <br />                                             expressed active TS enzyme (data shown). experiments demonstrated <br />                                             unambiguously amino-terminal DHFR domain malarial DHFR-TS necessary <br />                                             carboxyl-terminal TS sequence gain TS function. TS31 domain                                             rescued DHFR domain (data shown), &#226;&#8364;&#339;joining region&#226;&#8364;? make <br />                                             significant contacts malarial DHFR domain. requirement DHFR domain <br />                                             species-specific endogenous E. coli DHFR activate malarial TS <br />                                             sequence expressed bacterial host. <br />  <br />  <br />  <br />  <br />                                                 J Biol Chem. Author manuscript; available PMC 2013 October 07. <br />                             Shallom et al.                                                                                              Page 6 <br />  <br />  <br />                               Physical Associations Split Protein <br />                                             general ways malarial DHFR domain activating TS <br />                                             function TS domain:   DHFR domain acted transient chaperon <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             folding TS sequence, (ii) DHFR domain formed stable <br />                                             association carboxyl-terminal TS. determine stable association <br />                                             DHFR TS domains split protein, physical characteristics                                             active proteins double transformed E. coli studied.  cell lysate E. <br />                                             coli Rue10(DE3) pET-DHFR, pET-TS40, subjected gel filtration chromatography. <br />                                             TS activity malarial DHFR emerged single superimposing peak (Fig. 4A). size <br />                                             TS + DHFR complex 140,000 daltons. consistent hypothesis <br />                                             DHFR TS fragments assembled tetramer 40-kDa TS <br />                                             units 27-kDa DHFR units, reestablishing natural relationship                                             domains. reasonable alternative structures inconsistent gel filtration data. <br />                                             free DHFR domain mass 27 kDa seen gel filtration column.                                             did DHFR-free obligate TS dimer mass 80 kDa. <br />  <br />                                             TS + DHFR split protein formed complex stable survive gel filtration <br />                                             chromatography, chose purify complex homogeneity study physical <br />                                             characteristics. Cell lysates double-transformed E. coli Rue10(DE3) passed <br />                                             methotrexate affinity column, known bind malarial DHFR domain <br />                                             (32). unbound protein eluted 500 mM salt, specifically bound protein NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             eluted 4 mM dihydrofolate (Fig. 4B). TS activity malarial DHFR <br />                                             activities eluted simultaneously 4 mM dihydrofolate fractions. active fractions <br />                                             concentrated subjected SDS-polyacrylamide gel electrophoresis (Fig. 4C). <br />                                             Coomassie Blue staining revealed bands, mass 40 kDa                                             mass 27 kDa. Careful densitometry revealed 27- 40-kDa bands                                             present stoichiometric ratio 1 0.97, compensating size differences.                                             larger 40-kDa band labeling radioactive 5-fluoro-2&#226;&#8364;&#178;-deoxyuridylate                                             predict catalytically active TS domain (Fig. 4C). smaller band, 27-kDa, <br />                                             shown malarial DHFR domain Western blotting (Fig. 4C). final purified <br />                                             material DHFR-specific activity 39.2 &#206;&#188;mol/min/mg total protein. Assuming                                             kcat 1800/min DHFR, consistent protein having 27-kDa <br />                                             DHFR subunits attached 40-kDa TS subunits. sum, physical characteristics                                             purified split protein support gel filtration studies consistent model <br />                                             DHFR TS domains assemble form 140-kDa tetramer.                                             experiments interactions DHFR domain TS domain                                             lead activation TS function transient; split malarial DHFR domain                                             40-kDa domain reassemble form stable complex reflects natural state                                             bifunctional protein (Fig. 5). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             present study uses combination genetic biochemical approaches demonstrate <br />                                             species-specific interactions malarial DHFR domain TS domain                                             essential TS function. <br />  <br />                                             malarial DHFR-TS structure available, crystal structure Leishmania <br />                                             major DHFR-TS bifunctional protein offers obvious clue amino end                                             DHFR domain act determinant TS function. Leishmania enzyme 22- <br />                                             <span id='am-1' about='obo:IMR_0001695' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-2' property="obo:IAO_0000115" content="Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins." datatype="xsd:string"></span><span id='am-3' property="oboInOwl:hasDbXref" content="MeSH:D000596" datatype="xsd:string"></span><span id='am-4' property="oboInOwl:id" content="IMR:0001695" datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasDbXref" content="CHEBI:33709" datatype="xsd:string"></span><span id='am-6' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-7' property="rdfs:label" content="amino acid" datatype="xsd:string"></span>amino acid</span> extension amino terminus DHFR domain encircles                                             attached TS domain (28).  polypeptide extension amino end                                             DHFR domain appears necessary stabilize tertiary structure TS domain,                                             conceivable residues extended polypeptide contribute directly <br />                                             formation TS-active site. malarial DHFR shorter extension <br />                                             amino end (21), conceivable directly interacts residues TS <br />  <br />                                                 J Biol Chem. Author manuscript; available PMC 2013 October 07. <br />                             Shallom et al.                                                                                                             Page 7 <br />  <br />  <br />                                             domain necessary form catalytically active TS enzyme. course,                                             possible  unlike Leishmania bifunctional protein, amino end malarial <br />                                             DHFR domain necessary primarily stabilize DHFR tertiary structure  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             indirectly, influences correct folding activity malarial TS domain. <br />  <br />                                             Regardless mechanistic details underlying activation TS domain amino <br />                                             end DHFR domain, inhibition species-specific protein-protein interactions <br />                                             offer powerful new strategy selective chemotherapy malaria possibly <br />                                             protozoan parasites. Small molecular weight peptidomimetics disrupt                                             interactions domains fail activate TS expected inhibit malarial TS <br />                                             selectivity human TS does require &#226;&#8364;&#339;activation&#226;&#8364;? accessory protein. <br />                                             precedence drug development inspired species-specific protein-protein <br />                                             interactions. instance, virus-specific interactions subunits                                             ribonucleotide reductase herpes simplex virus led selective peptidomimetic <br />                                             inhibitors effective nanomolar concentrations (40). addition, inhibition                                             protein-protein interactions considered systems including dimerization                                             HIV proteases, assembly herpes simplex virus DNA polymerase subunits, interactions <br />                                             involving G-proteins signal transduction machinery, binding adhesion molecules <br />                                             surface proteins platelets (41). <br />  <br />                                             present E. coli genetic assay malarial TS function expected play powerful role <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             future mutagenesis experiments help establish contact sites                                             malarial protein domains. addition, present genetic serve high <br />                                             throughput screens identify selective inhibitors malarial TS function. Finally,                                             present  hybrid&#226;&#8364;? genetic provides novel means maintaining plasmids <br />                                             indefinitely selectable drug marker. <br />  <br />                               Acknowledgments <br />                                             P. K. R. grateful Chen-Chen Kan (Agouron Pharmaceuticals) E. coli Rue10 cells, John Hyde <br />                                             (University Manchester) length DHFR-TS gene, Dan Herschlag, (Stanford University)                                             valuble discussions. <br />  <br />  <br />                               References <br />                                             1. Oaks, SC., Jr; Mitchell, VS.; Pearson, GW.; Pearson, CCJ., editors. Malaria. National Academy <br />                                                Press; Washington, D. C: 1991. <br />                                             2. White NJ. J Antimicrob Chemother. 1992; 30:571&#226;&#8364;&#8220;585. [PubMed: 1493976] <br />                                             3. Su XZ, Kirkman LA, Fujioka H, Wellems TA. Cell. 1997; 91:593&#226;&#8364;&#8220;603. [PubMed: 9393853] <br />                                             4. Rathod PK, McErlean T, Lee PC. Proc Natl Acad Sci U S  1997; 94:9389&#226;&#8364;&#8220;9393. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                9256492] <br />                                             5. White NJ, Olliaro PL. Parasitol Today. 1996; 12:399&#226;&#8364;&#8220;401. [PubMed: 15275291] <br />                                             6. Hillcoat BL, Blakely RL. J Biol Chem. 1966; 241:2995&#226;&#8364;&#8220;3001. [PubMed: 4957970] <br />                                             7. Hitchings GH. Clin Pharmacol Ther. 1960; 1:570&#226;&#8364;&#8220;589. <br />                                             8. Houghton PJ, Germain GS, Hazelton BJ, Pennington JW, Houghton JA. Proc Natl Acad Sci U S  <br />                                                1989; 86:1377&#226;&#8364;&#8220;1381. [PubMed: 2537495] <br />                                             9. Ingraham HA, Dickey L, Goulian M. Biochemistry. 1986; 25:3225&#226;&#8364;&#8220;3230. [PubMed: 3524674] <br />                                             10. Yoshioka  Tanaka S, Hiraoka O, Koyama Y, Hirota Y, Ayusawa D, Seno T, Garrett C, Wataya <br />                                                  Y. J Biol Chem. 1987; 262:8235&#226;&#8364;&#8220;8241. [PubMed: 2954951] <br />                                             11. Hitchings GH. Clin Pharmacol Ther. 1960; 1:570&#226;&#8364;&#8220;589. <br />                                             12. Russel PB, Hitchings GH. J Chem Soc. 1951; 73:3763&#226;&#8364;&#8220;3770. <br />                                             13. Spinks  Tottey MM. Ann Trop Med. 1945; 39:220&#226;&#8364;&#8220;224. <br />  <br />  <br />  <br />  <br />                                                  J Biol Chem. Author manuscript; available PMC 2013 October 07. <br />                             Shallom et al.                                                                                             Page 8 <br />  <br />  <br />                                             14. Foote SJ, Galatis D, Cowman AF. Proc Natl Acad Sci U S  1990; 87:3014&#226;&#8364;&#8220;3017. [PubMed: <br />                                                 2183221] <br />                                             15. Peterson DS, Milhous WK, Wellems TE. Proc Natl Acad Sci U S  1990; 87:3018&#226;&#8364;&#8220;3022. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                 [PubMed: 2183222] <br />                                             16. Nzila-Mounda  Mberu EK, Sibley CH, Plowe CV, Winstanley PA, Watkins WM. Antimicrob <br />                                                 Agents Chemother. 1998; 42:164&#226;&#8364;&#8220;169. [PubMed: 9449279] <br />                                             17. Canfield CJ, Milhous WK, Ager AL, Rossan RN, Sweeney TR, Lewis NJ, Jacobus DP. J Trop <br />                                                 Med Hyg. 1993; 49:121&#226;&#8364;&#8220;126. [PubMed: 8352384] <br />                                             18. Winstanley PA, Mberu EK, Szwandt  Breckenridge  Watkins WM. Antimicrob Agents <br />                                                 Chemother. 1995; 39:948&#226;&#8364;&#8220;952. [PubMed: 7786001] <br />                                             19. Hekmat-Nejad M, Rathod PK. Exp Parasitol. 1997; 87:222&#226;&#8364;&#8220;228. [PubMed: 9371087] <br />                                             20. Rathod PK, Reshmi S. Antimicrob Agents Chemother. 1994; 38:476&#226;&#8364;&#8220;480. [PubMed: 8203840] <br />                                             21. Bzik DJ, Li W, Horii T, Insulburg J. Proc Natl Acad Sci U S  1987; 84:8360&#226;&#8364;&#8220;8364. [PubMed: <br />                                                 2825189] <br />                                             22. Beverley SM, Ellenberg TE, Cordingley JS. Proc Natl Acad Sci U S  1986; 83:2584&#226;&#8364;&#8220;2588. <br />                                                 [PubMed: 3458220] <br />                                             23. Chen G, Zolg JW. Mol Pharmacol. 1987; 32:723&#226;&#8364;&#8220;730. [PubMed: 3320742] <br />                                             24. Garrett CE, Coderre JA, Meek TD, Garvey EP, Claman D, Beverly SM, Santi DV. Mol Biochem <br />                                                 Parasitol. 1984; 11:257&#226;&#8364;&#8220;265. [PubMed: 6749182] <br />                                             25. Huennekans FM. Protein Sci. 1996; 5:1201&#226;&#8364;&#8220;1208. [PubMed: 8762155] <br />                                             26. Carreras CW, Santi DV. Annu Rev Biochem. 1995; 64:721&#226;&#8364;&#8220;762. [PubMed: 7574499] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             27. Meek TD, Garvey EP, Santi DV. Biochemistry. 1985; 24:678&#226;&#8364;&#8220;686. [PubMed: 3922404] <br />                                             28. Knighton RR, Kan CC, Howland E, Janson CA, Hostomska  Welsh KM, Mathews DA. Nat <br />                                                 Struct Biol. 1994; 1:186&#226;&#8364;&#8220;194. [PubMed: 7656037] <br />                                             29. Elcock AH, Potter MJ, Matthews DA, Knighton DR, McCammon JA. J Mol Biol. 1996; 262:370&#226;&#8364;&#8220; <br />                                                 374. [PubMed: 8845002] <br />                                             30. Trujillo M, Donald RG, Roos DS, Greene PJ, Santi DV. Biochemistry. 1996; 35:6366&#226;&#8364;&#8220;6374. <br />                                                 [PubMed: 8639582] <br />                                             31. Hekmat-Nejad M, Rathod PK. Antimicrob Agents Chemother. 1996; 40:1628&#226;&#8364;&#8220;1632. [PubMed: <br />                                                 8807052] <br />                                             32. Hekmat-Nejad M, Lee P, Rathod PK. Exp Parasito <br /> </body></html>